Exploring Metallodrug-protein Interactions by Mass Spectrometry: Comparisons Between Platinum Coordination Complexes and an Organometallic Ruthenium Compound

Overview

Journal J Biol Inorg Chem

Publisher Springer

Specialty Biochemistry

Date 2009 Mar 17

PMID 19288144

Citations 21

Authors

Angela Casini

Chiara Gabbiani

Elena Michelucci

Giuseppe Pieraccini

Gloriano Moneti

Paul J Dyson

Luigi Messori

Affiliations

Soon will be listed here.

Abstract

Electrospray ionisation mass spectrometry was used to analyse the reactions of metal compounds with mixtures of selected proteins. Three representative medicinally relevant compounds, cisplatin, transplatin and the organometallic ruthenium compound RAPTA-C, were reacted with a pool of three proteins, ubiquitin, cytochrome c and superoxide dismutase, and the reaction products were analysed using high-resolution mass spectrometry. Highly informative electrospray ionisation mass spectra were acquired following careful optimisation of the experimental conditions. The formation of metal-protein adducts was clearly observed for the three proteins. In addition, valuable information was obtained on the nature of the protein-bound metallofragments, on their distribution among the three different proteins and on the binding kinetics. The platinum compounds were less reactive and considerably less selective in protein binding than RAPTA-C, which showed a high affinity towards ubiquitin and cytochrome c, but not superoxide dismutase. In addition, competition studies between cisplatin and RAPTA-C showed that the two metallodrugs have affinities for the same amino acid residues on protein binding.

Citing Articles

AdductHunter: identifying protein-metal complex adducts in mass spectra.

Long D, Eade L, Sullivan M, Dost K, Meier-Menches S, Goldstone D J Cheminform. 2024; 16(1):15.

PMID: 38321500 PMC: 10845562. DOI: 10.1186/s13321-023-00797-7.

Dichloro Ru(II)--cymene-1,3,5-triaza-7-phosphaadamantane (RAPTA-C): A Case Study.

Swaminathan S, Karvembu R ACS Pharmacol Transl Sci. 2023; 6(7):982-996.

PMID: 37470017 PMC: 10353064. DOI: 10.1021/acsptsci.3c00085.

Determination of Relative Stabilities of Metal-Peptide Bonds in the Gas Phase.

Cziferszky M, Truong D, Hartinger C, Gust R Chemistry. 2021; 27(66):16401-16406.

PMID: 34554615 PMC: 9298285. DOI: 10.1002/chem.202102385.

Tuning Cyclometalated Gold(III) for Cysteine Arylation and Ligand-Directed Bioconjugation.

Gukathasan S, Parkin S, Black E, Awuah S Inorg Chem. 2021; 60(19):14582-14593.

PMID: 34402302 PMC: 8711130. DOI: 10.1021/acs.inorgchem.1c01517.

Gold-Based Pharmacophore Inhibits Intracellular MYC Protein.

Ofori S, Gukathasan S, Awuah S Chemistry. 2020; 27(12):4168-4175.

PMID: 33275307 PMC: 8605874. DOI: 10.1002/chem.202004962.

References

Gabbiani C, Casini A, Mastrobuoni G, Kirshenbaum N, Moshel O, Pieraccini G . Peculiar mechanistic and structural features of the carboplatin-cytochrome c system revealed by ESI-MS analysis. J Biol Inorg Chem. 2008; 13(5):755-64. DOI: 10.1007/s00775-008-0361-z. View

Reedijk J . New clues for platinum antitumor chemistry: kinetically controlled metal binding to DNA. Proc Natl Acad Sci U S A. 2003; 100(7):3611-6. PMC: 152970. DOI: 10.1073/pnas.0737293100. View

Pintus G, Tadolini B, Posadino A, Sanna B, Debidda M, Bennardini F . Inhibition of the MEK/ERK signaling pathway by the novel antimetastatic agent NAMI-A down regulates c-myc gene expression and endothelial cell proliferation. Eur J Biochem. 2002; 269(23):5861-70. DOI: 10.1046/j.1432-1033.2002.03307.x. View

Vessieres A, Top S, Beck W, Hillard E, Jaouen G . Metal complex SERMs (selective oestrogen receptor modulators). The influence of different metal units on breast cancer cell antiproliferative effects. Dalton Trans. 2006; (4):529-41. DOI: 10.1039/b509984f. View

Calderone V, Casini A, Mangani S, Messori L, Orioli P . Structural investigation of cisplatin-protein interactions: selective platination of His19 in a cuprozinc superoxide dismutase. Angew Chem Int Ed Engl. 2006; 45(8):1267-9. DOI: 10.1002/anie.200502599. View

Casini A, Mastrobuoni G, Temperini C, Gabbiani C, Francese S, Moneti G . ESI mass spectrometry and X-ray diffraction studies of adducts between anticancer platinum drugs and hen egg white lysozyme. Chem Commun (Camb). 2006; (2):156-8. DOI: 10.1039/b611122j. View

Timerbaev A, Hartinger C, Aleksenko S, Keppler B . Interactions of antitumor metallodrugs with serum proteins: advances in characterization using modern analytical methodology. Chem Rev. 2006; 106(6):2224-48. DOI: 10.1021/cr040704h. View

Cristoni S, Bernardi L . Development of new methodologies for the mass spectrometry study of bioorganic macromolecules. Mass Spectrom Rev. 2003; 22(6):369-406. DOI: 10.1002/mas.10062. View

Alessio E, Mestroni G, Bergamo A, Sava G . Ruthenium antimetastatic agents. Curr Top Med Chem. 2004; 4(15):1525-35. DOI: 10.2174/1568026043387421. View

10.

Noor R, Mittal S, Iqbal J . Superoxide dismutase--applications and relevance to human diseases. Med Sci Monit. 2002; 8(9):RA210-5. View

11.

Casini A, Hartinger C, Gabbiani C, Mini E, Dyson P, Keppler B . Gold(III) compounds as anticancer agents: relevance of gold-protein interactions for their mechanism of action. J Inorg Biochem. 2008; 102(3):564-75. DOI: 10.1016/j.jinorgbio.2007.11.003. View

12.

Pickart C, Eddins M . Ubiquitin: structures, functions, mechanisms. Biochim Biophys Acta. 2004; 1695(1-3):55-72. DOI: 10.1016/j.bbamcr.2004.09.019. View

13.

Scolaro C, Bergamo A, Brescacin L, Delfino R, Cocchietto M, Laurenczy G . In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes. J Med Chem. 2005; 48(12):4161-71. DOI: 10.1021/jm050015d. View

14.

Casini A, Gabbiani C, Mastrobuoni G, Pellicani R, Intini F, Arnesano F . Insights into the molecular mechanisms of protein platination from a case study: the reaction of anticancer platinum(II) iminoethers with horse heart cytochrome c. Biochemistry. 2007; 46(43):12220-30. DOI: 10.1021/bi701516q. View

15.

Brabec V . DNA modifications by antitumor platinum and ruthenium compounds: their recognition and repair. Prog Nucleic Acid Res Mol Biol. 2002; 71:1-68. DOI: 10.1016/s0079-6603(02)71040-4. View

16.

Casini A, Gabbiani C, Sorrentino F, Rigobello M, Bindoli A, Geldbach T . Emerging protein targets for anticancer metallodrugs: inhibition of thioredoxin reductase and cathepsin B by antitumor ruthenium(II)-arene compounds. J Med Chem. 2008; 51(21):6773-81. DOI: 10.1021/jm8006678. View

17.

Will J, Sheldrick W, Wolters D . Characterisation of cisplatin coordination sites in cellular Escherichia coli DNA-binding proteins by combined biphasic liquid chromatography and ESI tandem mass spectrometry. J Biol Inorg Chem. 2007; 13(3):421-34. DOI: 10.1007/s00775-007-0333-8. View

18.

Natile G, Coluccia M . Antitumor active trans-platinum compounds. Met Ions Biol Syst. 2004; 42:209-50. View

19.

Peleg-Shulman T, Najajreh Y, Gibson D . Interactions of cisplatin and transplatin with proteins. Comparison of binding kinetics, binding sites and reactivity of the Pt-protein adducts of cisplatin and transplatin towards biological nucleophiles. J Inorg Biochem. 2002; 91(1):306-11. DOI: 10.1016/s0162-0134(02)00362-8. View

20.

Casini A, Mastrobuoni G, Ang W, Gabbiani C, Pieraccini G, Moneti G . ESI-MS characterisation of protein adducts of anticancer ruthenium(II)-arene PTA (RAPTA) complexes. ChemMedChem. 2007; 2(5):631-5. DOI: 10.1002/cmdc.200600258. View